WCM
ALXO icon

Westend Capital Management’s ALX Oncology ALXO Stock Holding History

Westend Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-74
Closed -$825 – 235
2024
Q1 		$825 Buy
+74
New +$1.04K ﹤0.01% 281

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Westend Capital Management's ALXO Position: Q2 2024 in Review

Westend Capital Management sold out of ALX Oncology (ALXO) in Q2 2024, closing a stake of 74 shares — an estimated $825 sold.

Westend Capital Management first reported a position in ALXO in Q1 2024 and held it in 1 quarter. The position peaked at $825 in Q1 2024. 111 funds tracked by Wall St. Rank hold ALXO as of Q2 2024.

  • Westend Capital Management reported no remaining ALX Oncology position as of Q2 2024 after selling out during the quarter.
  • Westend Capital Management sold 74 ALX Oncology shares in Q2 2024, an estimated $825.
  • Westend Capital Management first reported a position in ALX Oncology in Q1 2024 and held it in 1 quarter.
  • Westend Capital Management's ALX Oncology position peaked at $825 in Q1 2024.
  • 111 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2024.

Based on Westend Capital Management's 13F filing for Q2 2024, filed 8 Jul 2024.